Pfizer’s Xeljanz (tofacitinib), a JAK inhibitor originally approved to treat rheumatoid arthritis, has become the subject of a federal multidistrict litigation (MDL) after post-market studies revealed elevated risks of serious cardiovascular events, including heart attacks and strokes. The MDL, centralized in the Northern District of West Virginia, consolidates claims from patients who allege they suffered heart attacks, blood clots, strokes, and other major adverse cardiac events after taking Xeljanz — and that Pfizer knew or should have known about these risks earlier than it disclosed them.
For example, some plaintiffs claim they were prescribed Xeljanz for moderate-to-severe rheumatoid arthritis without being adequately warned that the drug carried a statistically significant increased risk of heart attack compared to TNF inhibitor alternatives like Humira or Enbrel. It also addresses practical considerations for anyone weighing whether to pursue a claim and what the landscape may look like going forward.
Table of Contents
- What Heart Risks Has Xeljanz Been Linked to and Why Is Pfizer Facing MDL Claims?
- What Did the FDA’s Safety Review and Boxed Warning Actually Say?
- How Is the Xeljanz MDL Structured and Where Does It Stand?
- Who May Be Eligible to File a Xeljanz Heart Risk Claim?
- What Challenges Do Plaintiffs Face in the Xeljanz Litigation?
- How Has the Xeljanz Litigation Affected the Broader JAK Inhibitor Market?
- What Is the Outlook for the Xeljanz MDL and Potential Settlements?
- Frequently Asked Questions
What Heart Risks Has Xeljanz Been Linked to and Why Is Pfizer Facing MDL Claims?
The core of the Xeljanz litigation traces back to a large post-marketing safety study known as ORAL Surveillance, which the FDA required Pfizer to conduct as a condition of the drug’s original 2012 approval. The study compared Xeljanz to TNF inhibitor therapies in rheumatoid arthritis patients aged 50 and older who had at least one cardiovascular risk factor. Results, which became public around 2021, showed that patients on Xeljanz faced a notably higher rate of major adverse cardiovascular events (MACE) — including heart attacks and strokes — as well as increased rates of blood clots, cancers, and death compared to those on TNF inhibitors. The FDA responded by requiring a boxed warning, the most serious type of safety warning on a prescription drug label, and restricting Xeljanz to patients who had not responded adequately to TNF inhibitor therapy.
Plaintiffs in the mdl allege that Pfizer had access to safety signals suggesting cardiovascular risk well before the ORAL Surveillance results were finalized, and that the company failed to adequately warn prescribing physicians and patients. The claims generally fall under theories of failure to warn, negligence, and strict product liability. Some plaintiffs point to the fact that Pfizer actively marketed Xeljanz as a convenient oral alternative to injectable biologics, which they argue encouraged broader prescribing without adequate risk disclosure. By comparison, injectable TNF inhibitors like adalimumab (Humira) and etanercept (Enbrel) had longer track records and more established safety profiles, making the lack of transparent risk communication around Xeljanz particularly consequential.
What Did the FDA’s Safety Review and Boxed Warning Actually Say?
In September 2021, the FDA issued a safety communication requiring significant label changes for Xeljanz and, notably, extended its concerns to the broader class of JAK inhibitors, including Olumiant (baricitoclast), and Rinvoq (upadacitinib). The updated boxed warning highlighted increased risks of serious heart-related events, cancer, blood clots, and death. The FDA also limited the approved use of these JAK inhibitors to patients who had an inadequate response or intolerance to one or more TNF blockers, effectively repositioning the entire drug class as a second-line treatment rather than a first-choice option. However, critics of the FDA’s response argue that the agency could have acted sooner.
The ORAL Surveillance study began enrolling patients in 2014, and interim safety signals were reportedly available years before the final results were published. If a patient was prescribed Xeljanz between its 2012 approval and the 2021 label change, and subsequently suffered a cardiovascular event, the question of what Pfizer knew and when becomes central to their legal claim. It is worth noting that the boxed warning applies to the drug class broadly, but the specific litigation is focused on Xeljanz because it was the first JAK inhibitor approved and the one for which the most extensive post-market data exists. Patients who took other JAK inhibitors may have separate legal pathways, but the Xeljanz MDL remains the most consolidated and advanced proceeding.
How Is the Xeljanz MDL Structured and Where Does It Stand?
The Xeljanz MDL was established by the Judicial Panel on Multidistrict Litigation and assigned to Judge Thomas S. Kleeh in the U.S. District court for the Northern District of West Virginia. MDL proceedings consolidate pretrial matters — including discovery, expert testimony challenges, and motion practice — from individual lawsuits filed across the country into a single court for efficiency. As of recent reports, the MDL has included a growing number of individual cases, though the exact current count fluctuates as new cases are filed and others are resolved or dismissed.
A critical milestone in any MDL is the selection and trial of bellwether cases. Bellwether trials serve as test cases that help both sides gauge the strength of their arguments and can influence settlement negotiations. In the Xeljanz MDL, the court has been working through the bellwether selection and preparation process, which involves choosing cases that are broadly representative of the overall litigation. For example, bellwether plaintiffs might include individuals who suffered heart attacks or strokes after taking Xeljanz for rheumatoid arthritis, with varying lengths of use and differing levels of pre-existing cardiovascular risk. The outcomes of these early trials often set the tone for how remaining cases are resolved, whether through further trials, individual settlements, or a global settlement agreement.
Who May Be Eligible to File a Xeljanz Heart Risk Claim?
Generally, individuals who were prescribed and took Xeljanz (tofacitinib) and subsequently experienced a serious cardiovascular event may be eligible to pursue a claim. The types of injuries most commonly alleged in the litigation include heart attacks, strokes, deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic events. Eligibility often depends on several factors: the duration and timing of Xeljanz use, whether the cardiovascular event occurred during or shortly after taking the medication, and whether the patient had pre-existing heart conditions that might complicate causation arguments. One important tradeoff to understand is that having pre-existing cardiovascular risk factors does not necessarily disqualify someone from filing a claim.
In fact, the ORAL Surveillance study specifically enrolled patients with at least one cardiovascular risk factor, which means the elevated risk identified in the study was observed precisely in the population most likely to be prescribed the drug. However, Pfizer’s defense is expected to argue in many cases that a plaintiff’s heart attack or stroke was caused by their underlying health conditions rather than by Xeljanz. This makes thorough medical documentation and expert testimony critical for individual claims. Prospective claimants should also be aware that statutes of limitations vary by state, and the clock for filing may have started running at the time of injury or at the time they learned — or reasonably should have learned — about the connection between Xeljanz and their cardiac event.
What Challenges Do Plaintiffs Face in the Xeljanz Litigation?
Causation is typically the most contested issue in pharmaceutical litigation, and the Xeljanz MDL is no exception. Pfizer is expected to mount a vigorous defense arguing that its labeling was adequate at the time of prescribing, that the risks were disclosed as they became known, and that individual plaintiffs’ cardiovascular events were attributable to their own risk factors — age, smoking history, obesity, diabetes, hypertension — rather than the drug itself. The company may also argue that physicians exercised independent medical judgment in prescribing Xeljanz and were aware of the drug’s risk profile. Another challenge is the learned intermediary doctrine, which in many states shields pharmaceutical companies from failure-to-warn claims directed at patients by arguing that the duty to warn runs to the prescribing physician, not the end user.
Under this doctrine, if Pfizer provided adequate warnings to doctors, it may argue it fulfilled its legal obligations even if the patient was never personally informed of the cardiac risks. Plaintiffs’ attorneys counter this by arguing that Pfizer’s marketing and promotional efforts downplayed or obscured the risks in a way that influenced physician prescribing behavior. Additionally, some claimants may face difficulty obtaining complete medical records or establishing a clear timeline between Xeljanz use and their cardiac event, particularly if significant time has passed. Anyone considering a claim should be prepared for a process that can take years and should ensure they preserve all relevant medical records and pharmacy records.
How Has the Xeljanz Litigation Affected the Broader JAK Inhibitor Market?
The fallout from the Xeljanz safety concerns and subsequent litigation has had ripple effects across the JAK inhibitor drug class. After the FDA’s 2021 label changes, prescribing patterns shifted noticeably, with many rheumatologists moving patients back to TNF inhibitors or other biologic therapies as first-line treatments. Pfizer reported declines in Xeljanz revenue in the quarters following the boxed warning update, and competitors developing newer JAK inhibitors faced heightened regulatory scrutiny.
For instance, AbbVie’s Rinvoq (upadacitinib) and Eli Lilly’s Olumiant (baricitinib) were also required to carry similar boxed warnings, even though neither had completed the same type of large-scale cardiovascular outcomes study that generated the Xeljanz data. This created an unusual dynamic where an entire drug class was penalized based largely on data from a single member of that class. Some physicians and patient advocates have argued that this approach may be overly broad, potentially denying effective treatment to patients who might benefit from JAK inhibitors without facing the same level of risk. Nevertheless, the regulatory and litigation landscape has made it clear that the burden of proof for cardiovascular safety in this drug class is now substantially higher than it was when Xeljanz first came to market.
What Is the Outlook for the Xeljanz MDL and Potential Settlements?
As of recent reports, the Xeljanz MDL remains active, with bellwether case preparation continuing and new cases still being filed. The timeline for any potential global settlement remains uncertain, as it typically depends on the outcomes of initial bellwether trials and the volume of qualified claims in the litigation. Historically, large pharmaceutical MDLs involving widely prescribed drugs and serious injuries have resulted in substantial settlement funds, but the amounts and terms vary enormously depending on the strength of the evidence, the number of claimants, and the defendant’s willingness to negotiate.
Patients who believe they may have a claim should not wait indefinitely to seek legal counsel, as statutes of limitations continue to run and evidence can become harder to obtain over time. The litigation landscape can also shift quickly — a favorable bellwether verdict for plaintiffs could accelerate settlement talks, while a defense verdict could slow momentum. Anyone affected should stay informed through official court filings and consult with an attorney experienced in pharmaceutical mass tort litigation to understand their individual options and timelines.
Frequently Asked Questions
What is the Xeljanz MDL about?
The Xeljanz MDL consolidates federal lawsuits from patients who allege they suffered serious cardiovascular events — such as heart attacks, strokes, and blood clots — after taking Pfizer’s JAK inhibitor drug Xeljanz (tofacitinib), and that Pfizer failed to adequately warn about these risks.
What injuries are associated with Xeljanz claims?
The most commonly alleged injuries include heart attacks, strokes, deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic events. Some claims also involve cancer diagnoses and death.
Does having pre-existing heart conditions disqualify someone from filing a claim?
Not necessarily. The clinical study that identified the increased cardiovascular risk specifically enrolled patients who already had at least one cardiovascular risk factor, so having pre-existing conditions does not automatically bar a claim. However, Pfizer may argue that individual events were caused by underlying health issues rather than the drug.
Is there a deadline to file a Xeljanz lawsuit?
Yes. Statutes of limitations vary by state and typically begin running either at the time of injury or when the patient discovered (or should have discovered) the connection between Xeljanz and their cardiovascular event. Consulting an attorney promptly is advisable to avoid missing applicable deadlines.
Has there been a Xeljanz settlement yet?
As of recent reports, there has not been a publicly announced global settlement in the Xeljanz MDL. The litigation is ongoing, with bellwether trial preparation underway. Settlement negotiations may follow initial trial outcomes.
Are other JAK inhibitors included in the Xeljanz MDL?
The Xeljanz MDL specifically concerns tofacitinib (Xeljanz). However, the FDA has applied similar boxed warnings to other JAK inhibitors, and separate legal actions involving those drugs may exist or develop independently.